Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandro Balsa

Showing results (51-60 of 246) with videos related to

Pageof 25
Sort By:
Annals of the Rheumatic Diseases|August 2, 2007
Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonistsIsidoro González-Alvaro, Ana M Ortiz, Eva G Tomero, et al.
International Journal of Clinical Pharmacy|September 10, 2018
Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in priceMariángeles González-Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, et al.
The Journal of Rheumatology|May 3, 2006
Role of SLC22A4, SLC22A5, and RUNX1 genes in rheumatoid arthritisAlfonso Martínez, Antonio Valdivia, Dora Pascual-Salcedo, et al.
Current Medical Research and Opinion|March 31, 2017
Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related)Bruno Fautrel, Alejandro Balsa, Piet Van Riel, et al.
Reumatologia Clinica|April 12, 2026
Treatment of rheumatoid arthritis-associated interstitial lung disease: What is new since the 2022 SER-SEPAR recommendations?Javier Narváez, Petra Díaz Del Campo Fontecha, M Asunción Nieto, et al.
Reumatologia Clinica|November 3, 2018
Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and SpondyloarthritisJosé Rosas, María Martín-López, Teresa Otón, et al.
Rheumatology International|June 9, 2016
Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a reviewEmilio Martin-Mola, Alejandro Balsa, Rosario García-Vicuna, et al.
BMC Bioinformatics|May 21, 2010
CNstream: a method for the identification and genotyping of copy number polymorphisms using Illumina microarraysArnald Alonso, Antonio Julià, Raül Tortosa, et al.
Reumatologia Clinica|June 28, 2025
Study of the impact of the inclusion of global pain and functional capacity assessment in the definition of remission and its maintenance for rheumatoid arthritis. Aims and methodologyAlejandro Balsa, Daniel Seoane-Mato, Marta Domínguez-Álvaro, et al.
Reumatologia Clinica|July 29, 2011
[The therapeutic blockade of TNF reduces serum levels of interleukin 15 in patients with rheumatoid arthritis]Isidoro González-Álvaro, Ana M Ortiz, Eva G Tomero, et al.
Pageof 25

Showing results (51-60 of 246) with videos related to

Sort By:
Pageof 25
Annals of the Rheumatic Diseases|August 2, 2007
Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonistsIsidoro González-Alvaro, Ana M Ortiz, Eva G Tomero, et al.
International Journal of Clinical Pharmacy|September 10, 2018
Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in priceMariángeles González-Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, et al.
The Journal of Rheumatology|May 3, 2006
Role of SLC22A4, SLC22A5, and RUNX1 genes in rheumatoid arthritisAlfonso Martínez, Antonio Valdivia, Dora Pascual-Salcedo, et al.
Current Medical Research and Opinion|March 31, 2017
Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related)Bruno Fautrel, Alejandro Balsa, Piet Van Riel, et al.
Reumatologia Clinica|April 12, 2026
Treatment of rheumatoid arthritis-associated interstitial lung disease: What is new since the 2022 SER-SEPAR recommendations?Javier Narváez, Petra Díaz Del Campo Fontecha, M Asunción Nieto, et al.
Reumatologia Clinica|November 3, 2018
Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and SpondyloarthritisJosé Rosas, María Martín-López, Teresa Otón, et al.
Rheumatology International|June 9, 2016
Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a reviewEmilio Martin-Mola, Alejandro Balsa, Rosario García-Vicuna, et al.
BMC Bioinformatics|May 21, 2010
CNstream: a method for the identification and genotyping of copy number polymorphisms using Illumina microarraysArnald Alonso, Antonio Julià, Raül Tortosa, et al.
Reumatologia Clinica|June 28, 2025
Study of the impact of the inclusion of global pain and functional capacity assessment in the definition of remission and its maintenance for rheumatoid arthritis. Aims and methodologyAlejandro Balsa, Daniel Seoane-Mato, Marta Domínguez-Álvaro, et al.
Reumatologia Clinica|July 29, 2011
[The therapeutic blockade of TNF reduces serum levels of interleukin 15 in patients with rheumatoid arthritis]Isidoro González-Álvaro, Ana M Ortiz, Eva G Tomero, et al.
Pageof 25